Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study
Research output: Contribution to journal › Journal article › Research › peer-review
- Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study
Final published version, 3.58 MB, PDF document
BACKGROUND: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are gut hormones secreted in response to food ingestion, and they have been suggested to regulate bone turnover. In humans, exogenous GIP and GLP-2 acutely inhibit bone resorption as measured by circulating levels of carboxy-terminal type 1 collagen crosslinks (CTX).
OBJECTIVE: The objective was to study the individual and combined acute effects of GIP and GLP-2 on bone turnover in postmenopausal women during nighttime - a period of increased bone resorption.
METHODS: Using a randomized, placebo-controlled, double-blinded, crossover design, each participant (n = 9) received on four separate study days: GIP, GLP-2, GIP + GLP-2, and placebo (saline) as subcutaneous injections at bedtime. Main outcomes were levels of CTX and procollagen type 1 N-terminal propeptide (P1NP).
RESULTS: Compared with placebo, GIP and GLP-2 alone significantly inhibited bone resorption (measured by CTX). GIP rapidly reduced CTX levels in the period from 45 to 120 min after injection, while GLP-2 had a more delayed effect with reduced CTX levels in the period from 120 to 240 min after injection. Combining GIP and GLP-2 showed complementary effects resulting in a sustained inhibition of CTX with reduced levels from 45 to 240 min after injection. Furthermore, GIP acutely increased bone formation (measured by P1NP).
CONCLUSION: Both GIP and GLP-2 reduced CTX during the night and had complementary effects when combined.
|Number of pages||7|
|Publication status||Published - 2021|
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.